Glofitamab is a CD20xCD3 bispecific antibody developed by F. Hoffmann-La Roche for the treatment of Non-Hodgkin Lymphoma. The FDA is likely to approve glofitamab for the treatment of Non-Hodgkin Lymphoma.
Glofitamab is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for Non-Hodgkin...
Willing to pay more for genuine iPhone parts. Choice should be mine.
– Apple is making $9 billion a year from subscriptions, including AppleCare+. – Apple’s grip on repairs incentivizes buyers to go for AppleCare, a route...
Weekend deals: save 28% on Razer Viper V3 HyperSpeed mouse
The author is recommending 8 hardware deals for gamers this holiday season. Link to the original story: https://cogconnected.com/2023/11/weekend-deals-including-28-off-razer-viper-v3-hyperspeed-mouse/...
10 great 2023 games you might have missed: – Scorn – The Callisto Protocol – Starfield – Tunic – The Last of Us Part 1 – Wo Long: Fallen Dynasty – A Plague Tale: Requiem – Avatar: Frontiers of Pandora – Dragon Age: Dreadwolf – Final Fantasy 16
10 hidden gems of 2023 that you might have missed: 1. Tin Hearts 2. Song of Nunu: A League of Legends Story 3. Gunbrella 4....
Are you a Carrie, Samantha, Charlotte or Miranda? Scientists say all singletons fit into four categories. Take the test to find out which one you are.
Are YOU a Carrie, Samantha, Charlotte or Miranda? Scientist claims all singletons fit into four categories – take the test to find out which one...
Tech Innovations for Disaster Resilience
Tech Innovations for Disaster Resilience Introduction Disasters can strike at any moment, causing widespread devastation and loss of life. However, with advancements in technology, there...
DCR-STAT3 is a Dicerna Pharmaceuticals drug candidate for the treatment of solid tumors. It is a small interfering RNA (siRNA) that targets the STAT3 gene. STAT3 is a transcription factor that is involved in cell growth and survival. By targeting STAT3, DCR-STAT3 could inhibit the growth and survival of cancer cells. DCR-STAT3 has been shown to be effective in preclinical studies in a variety of solid tumors. In a Phase 1 clinical trial, DCR-STAT3 was well-tolerated and showed promising antitumor activity. A Phase 2 clinical trial is currently underway to evaluate the efficacy and safety of DCR-STAT3 in patients with advanced solid tumors. Based on the available data, DCR-STAT3 has a high likelihood of approval for the treatment of solid tumors.
DCR-STAT3 is under clinical development by Dicerna Pharmaceuticals for Solid Tumor and has a 54% phase transition success rate (PTSR) indication benchmark for progressing into...
CH-0601 has a low likelihood of approval for the treatment of Type 1 Diabetes (Juvenile Diabetes).
CH-0601 is a Phase I drug for Type 1 Diabetes (Juvenile Diabetes) with a 73% phase transition success rate (PTSR) indication benchmark for progressing into...
Imee Marcos did not send Ilocos electric coop to restore power post-Yolanda.
Claim: As governor of Ilocos Norte in 2013, Imee Marcos sent the Ilocos Norte Electric Cooperative (INEC) to restore electricity to Leyte after the devastation...
The iPad is getting a new feature in 2024
– Apple is expected to release the first iPad Pro models with OLED displays in 2024. – The new iPad mini will be 8.7 inches...